Company news
Aptose Biosciences Inc news in 2025
Aptose Biosciences Inc's news releases, calls and decks from 2025, newest first.
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
December 19, 2025
Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
December 6, 2025
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
November 19, 2025
Aptose Reports Third Quarter 2025 Results
November 13, 2025
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
August 22, 2025
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
August 1, 2025
Decks in 2025
- Investor Presentation (March 2025)
Investor deck · 23 slides · Mar 12, 2025
- Investor Presentation (January 2025)
Investor deck · 20 slides · Jan 13, 2025